Modality
Gene Editing
MOA
PD-L1i
Target
PCSK9
Pathway
Complement
GARettAtopic Derm
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ Jun 2031
Phase 1Current
NCT04332586
10 pts·Atopic Derm
2020-06→2029-12·Recruiting
NCT08630766
1,099 pts·Atopic Derm
2018-07→2031-06·Active
1,109 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-12-053.7y awayInterim· Atopic Derm
2031-06-035.2y awayInterim· Atopic Derm
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1
Active
P1
Recruit…
Catalysts
Interim
2029-12-05 · 3.7y away
Atopic Derm
Interim
2031-06-03 · 5.2y away
Atopic Derm
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04332586 | Phase 1 | Atopic Derm | Recruiting | 10 | MRD |
| NCT08630766 | Phase 1 | Atopic Derm | Active | 1099 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 |